PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

Pfizer’s trading volume surged to $13.51 billion, more than doubling from the prior day. Despite the impressive spike in ...

Pfizer, which is generating billions of dollars from its Covid-19 vaccine, is investing in cancer drugs. Revenue last year from oncology was up more than 20 per cent from the year before to $10.9 ...

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three ...

Pfizer said it had made a profit of US$767m in Q4 2009, or earnings per share of US$0.10, compared to profits of US$266m, or earnings per share of US$0.04, made during the same quarter in 2008.

Irish staff of drug giant Pfizer are waiting to hear whether another round of cost-cutting, announced on Tuesday, will mean more job losses at the group’s Irish operations. Pfizer said it will ...

Apart from oncology, Pfizer’s portfolio has a variety of drugs and vaccines for diseases like COVID-19, inflammation & immunology diseases, rare diseases and migraine, among others. The Case for ...